



**NYSE:VNRX**

Our mission is to save lives and improve outcomes for millions of people and animals worldwide by advancing low-cost, epigenetic early detection and treatment monitoring tests.

Commercial launches worldwide in animal health (2022-2024); human products to follow

**Combined TAM >\$10 billion**

**Derisked R&D and Commercial Strategy: Reported First \$1 million Revenue 2024**

**Commercial Progress**

- Nu.Q® Vet Cancer test now available in 20 countries
- Solid >110,000 tests and test components Q1-Q3 2024
- Received \$23 million in upfront and milestone payments to-date
  - Additional \$5 million milestone payment (feline) anticipated 2025
- **Multiple international partnerships launched**
- **TAM >\$750 million**

**Revenue Expansion**

- Simple, low cost, recurring revenue generating tests performed on standard lab equipment
- **Clinical Partnering: multiple near-term licensing opportunities progressing**
- **Direct and indirect sales of CE-marked products in Europe, as hospitals evaluate for routine clinical use**

**Large Unmet Needs**

- **Lung Cancer Screening** – screening, prognostics and MRD represent a \$1.8B opportunity
- **Sepsis** – testing and monitoring ICU patients alone is a ~\$1B+ opportunity
- **Other addressable markets** of investigation include Acute Kidney Injury (AKI), Acute Respiratory Distress Syndrome (ARDS) and use in the Emergency Department **>\$10B** opportunity

**Strong IP**

- 18 patents granted
- 129 pending internationally
- Patent coverage up to 2044

**Licensing Portfolio: Platform stable, reproducible**

Application	Proof of Concept	Viability	Validation	Licensed
<b>Animal</b>				
Canine Cancer Screening	[Progress bar]			✓ <b>Launched</b>
Canine Cancer Monitoring	[Progress bar]			✓
Feline Cancer	[Progress bar]			✓
Automated tests	[Progress bar]			In negotiation
<b>Human</b>				
Sepsis	[Progress bar]			Data room available
Cancer	[Progress bar]			Data room available
Lung Cancer Screening	[Progress bar]			Data room available
Minimal Residual Disease & Disease Management	[Progress bar]			Data room available
Multi-Cancer Early Detection	[Progress bar]			Data room available
Capture-PCR™	[Progress bar]			Data room available

**NYSE Ticker: VNRX (ISIN US9286611077) <https://volition.com>**